检索结果 - Terrence P. Cescon
- Showing 1 - 3 results of 3
-
1
-
2
Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study 由 Jeffrey R. Infante, Tony R. Reid, Allen Lee Cohn, William J. Edenfield, Terrence P. Cescon, John Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim, Thomas H. Cartwright
出版 2013Artigo -
3
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors 由 Chun Wang, Zhaomei Mu, Zhong Ye, Zhenchao Zhang, Maysa Abu‐Khalaf, Daniel P. Silver, Juan Palazzo, Geetha Jagannathan, Frederick Fellin, Saveri Bhattacharya, Rebecca Jaslow, Theodore N. Tsangaris, Adam C. Berger, Manish Neupane, Terrence P. Cescon, AnaMaria Lopez, Kaelan Yao, Weelic Chong, Brian Lu, Ronald E. Myers, Lifang Hou, Qiang Wei, Bingshan Li, Massimo Cristofanilli, Hushan Yang
出版 2020Artigo
相关主题
Internal medicine
Medicine
Biology
Cancer
Chemotherapy
Oncology
Paleontology
Randomized controlled trial
Axitinib
Bevacizumab
Breast cancer
Clinical endpoint
Clinical psychology
Colorectal cancer
Confidence interval
Distress
FOLFOX
Family medicine
Gastroenterology
Gene
Genetic testing
Genetics
Hazard ratio
Intervention (counseling)
Multivariate analysis
Mutation
Oxaliplatin
Phases of clinical research
Proband
Progression-free survival